Dabrafenib (GSK2118436)

Catalog No.S2807

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Cited by 21 Publications

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )
Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

9 Customer Reviews

BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.
Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.
Braf−/− ER(TM)-HRAS(G12V) MEFs were transduced with retroviral constructs encoding the indicated BRAF proteins and treated with 4-HT to release oncogenic RAS, or ethanol as a control. Following incubation with 1 μM vemurafenib, 1 μM dabrafenib or DMSO as a control for 4 h, cells were subjected to western blot analysis with the indicated antibodies.

Leukemia, 2016, 30(4):937-46. Dabrafenib (GSK2118436) purchased from Selleck.

Western blots for untreated, early, and late tumors.

Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.
Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.
Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MnW4T4lv[XOnIFHzd4F6				MVLJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER\|M4KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO\|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1?	MVuyOFkxODZ5Mx?=
SK-MEL-28	MXTLbY5ie2ViQYPzZZk>		MmHHNUBp		MYXJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	NWTO[4RGOjR7MEC2O\|M>
HepG2	M2LCNWtqdmG\|ZTDBd5NigQ>?				M{P6VGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>?	Mme4NlQ6ODB4N{O=
COLO205	NEK2SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV2wR2UzUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPNlA2KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xODdizszN	NFHQZm8zPDlyME[3Ny=>
HepG2	MYHGeY5kfGmxbjDBd5NigQ>?		MYq0OUBucW5?	NGjueFJFVVOR	NVj6VpA5UW6qaXLpeIlwdiCxZjDBcIs2KGmwIGTHSk1j\XSjLYP0bY12dGG2ZXSgbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iU33h[FIheGixc4Doc5J6dGG2aX;uJJRz\WG2ZXSg[o9zKDR3IH3pcpMheHKrb4KgeI8hXEeILXLleIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhPjBibXnud{BjgSCxZInzd4V6KGKub4Sgd4Nidm6ncjDhcoFtgXOrczD3bZRpKEmFNUCgc4YhOy55IN88US=>	MXGyOFkxODZ5Mx?=
HFF	M4fLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TrWFExKM7:TR?=	NVf1NnpKPzJiaB?=	NHPKNHZFVVOR	NH;m[\|NKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR\|UxKG:oIEOg{txO	MUOyN\|g1PDB\|OB?=
SK-MEL-28	M{e1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3P5PVExKM7:TR?=	NWj2TFZ1PzJiaB?=	MVrEUXNQ	M3LmdmlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0>	NXuyfGp[OjN6NESwN\|g>
A375P-F11	NH;5O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHINVAh\|ryP	NHHnO204OiCq	NWXhc2x{TE2VTx?=	MlTyTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF\|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=>	NXHjb2JYOjN6NESwN\|g>
MALME-3M	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULaTZF4OTBizszN	M{XL[FczKGh?	NHPNNYRFVVOR	NVvlXWJWUUN3ME2xJI5O	NWPpZ2Q5OjN6NESwN\|g>
UACC-62	NHnNNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVG2Onc1OTBizszN	NF63NIM4OiCq	MYXEUXNQ	MkPtTWM2OD1zIH7N	M2Hac\|I{QDR2MEO4
C32TG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	NYWyOnBoPzJiaB?=	Mof0SG1UVw>?	M3\afWlEPTB;MTDuUS=>	NUfwfpZQOjN6NESwN\|g>
SK-MEL-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP5cIcyOCEQvF2=	M4ThPFczKGh?	M1nkS2ROW09?	MlHmTWM2OD1{IH7N	M{GyblI{QDR2MEO4
M14	NYLu[\|dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxNEDPxE1?	M3y0TFczKGh?	MXTEUXNQ	M1XxbWlEPTB;MjDuUS=>	NGSzZWYzOzh2NECzPC=>
SK-MEL-28	NYj6NlVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fxdlExKM7:TR?=	NGrBV2U4OiCq	M1vBU2ROW09?	NILzbYpKSzVyPUOgcm0>	NGDLbGwzOzh2NECzPC=>
A375	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3WydFExKM7:TR?=	MXK3NkBp	NWLER3czTE2VTx?=	NVPhZXRxUUN3ME20JI5O	NXTld\|R2OjN6NESwN\|g>
DU-4475	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXLdFhEOTBizszN	M1zEfVczKGh?	NG\teGZFVVOR	NUHFb3V4UUN3ME21JI5O	NXG3b5hSOjN6NESwN\|g>
UACC-257	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLTUXAyOCEQvF2=	NWHBRmMxPzJiaB?=	NX;pVJRpTE2VTx?=	MXjJR\|UxRTZibl2=	NEXMUXQzOzh2NECzPC=>
Colo 205	M3POdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XiTFExKM7:TR?=	M1\tUVczKGh?	MoXiSG1UVw>?	MYHJR\|UxRTdibl2=	MmHDNlM5PDRyM{i=
SK-MEL-3	NEniZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnERXg2OTBizszN	MXe3NkBp	M3i2[2ROW09?	MX3JR\|UxRTdibl2=	MV[yN\|g1PDB\|OB?=
SH-4	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfRSHMyOCEQvF2=	MlvVO\|IhcA>?	MmTuSG1UVw>?	M4jFcGlEPTB;ODDuUS=>	NGO3eXozOzh2NECzPC=>
A101D	NHLOZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfSVW0yOCEQvF2=	NEXud2o4OiCq	MnPISG1UVw>?	NWPQbWVEUUN3ME25JI5O	M1rwWVI{QDR2MEO4
ES-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rlU\|ExKM7:TR?=	MlzZO\|IhcA>?	Mn\vSG1UVw>?	M4Xa[mlEPTB;NUOgcm0>	M2P1eVI{QDR2MEO4
HT-29	NWLUb4J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITuPXoyOCEQvF2=	NEDvdIU4OiCq	MmPiSG1UVw>?	NFvGcZBKSzVyPU[2JI5O	MWCyN\|g1PDB\|OB?=
SW1417	NXLkdHoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDaVocyOCEQvF2=	M4izZ\|czKGh?	M2\ocmROW09?	NWWyem84UUN3ME2xOVghdk1?	MWqyN\|g1PDB\|OB?=
SW872	M3m0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DXN\|ExKM7:TR?=	M3;VdFczKGh?	MWTEUXNQ	MnHWTWM2OD1\|N{egcm0>	NUjQc2VuOjN6NESwN\|g>
RKO	M{nZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LnUVExKM7:TR?=	NV30XGV7PzJiaB?=	NVjDe3RkTE2VTx?=	NF\vZphKSzVyPUKuOVIzKM7:TR?=	NHewb4QzOzh2NECzPC=>
A673	NYHNOHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4H0fVExKM7:TR?=	MXe3NkBp	NX;0cFhGTE2VTx?=	NXOwT4NJUUN3ME2xNEDPxE1?	NIHJUIYzOzh2NECzPC=>
GCT	NEjYe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILISoEyOCEQvF2=	M3;SOlczKGh?	NHLRcGdFVVOR	NVjDOHh{UUN3ME2xNEDPxE1?	NGq5NFUzOzh2NECzPC=>
WM-115	M1XnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13kclExKM7:TR?=	MWq3NkBp	NFTWTI9FVVOR	NHm0dppKSzVyPUWgcm0>	NHHR[\|czOzh2NECzPC=>
YUMAC	NHr4[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[xNEDPxE1?	M1rSU\|czKGh?	MW\EUXNQ	MoDzTWM2OD13IH7N	NYPPVW9qOjN6NESwN\|g>
OV-90	NFjXOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYiwU\|M3OTBizszN	MUC3NkBp	MV7EUXNQ	NEXPeZhKSzVyPUK5JI5O	M4rydFI{QDR2MEO4
NCI-H508	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzZ[VgyOCEQvF2=	NF\JNoY4OiCq	NGPMW\|lFVVOR	MnnsTWM2OD1zMDFOwG0>	MUCyN\|g1PDB\|OB?=
MDA-MB-231	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXKxNEDPxE1?	Mo\wO\|IhcA>?	NUDaNIxZTE2VTx?=	NYflNWQ2UUN3ME2xNEDPxE1?	MVKyN\|g1PDB\|OB?=
SW756	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Cze\|ExKM7:TR?=	MYe3NkBp	NELkZYtFVVOR	MYDJR\|UxRTFyIN88US=>	Mn3CNlM5PDRyM{i=
SW-837	NIr1SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrMSG46OTBizszN	MmDkO\|IhcA>?	MWXEUXNQ	Mnj5TWM2OD1zMDFOwG0>	M{PLNFI{QDR2MEO4
UMUC-3	NUTx[4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXixNEDPxE1?	MmTuO\|IhcA>?	M2Tic2ROW09?	NIL0XlZKSzVyPUGwJO69VQ>?	MYWyN\|g1PDB\|OB?=
LS-174T	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTRXmpJOTBizszN	MlXoO\|IhcA>?	MmC0SG1UVw>?	Mn7FTWM2OD1zMDFOwG0>	Mlv3NlM5PDRyM{i=
A549	NYPDd5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X5PFExKM7:TR?=	NHz4WVE4OiCq	M1nhb2ROW09?	M{DX[2lEPTB;MUCg{txO	NXLENZlEOjN6NESwN\|g>
SHP-77	NGnOcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWmxNEDPxE1?	MYC3NkBp	MV7EUXNQ	M2nZN2lEPTB;MUCg{txO	NGiycGQzOzh2NECzPC=>
SW480	NVvDO\|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHxNVAh\|ryP	NGXke\|Y4OiCq	NW[wXJBVTE2VTx?=	NX7mUVM3UUN3ME2xNEDPxE1?	M3jENlI{QDR2MEO4
DLD-1	NYDF[\|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVv0UYtDOTBizszN	NX;2fplNPzJiaB?=	MkLXSG1UVw>?	NV;x[YM6UUN3ME2xNEDPxE1?	NHXTWXMzOzh2NECzPC=>
HCT-116	M4f1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzlNVAh\|ryP	NX3scpdIPzJiaB?=	NXLVZmRpTE2VTx?=	MXXJR\|UxRTFyIN88US=>	NEC5PJkzOzh2NECzPC=>
NCI-H747	NUK3d205T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYqxNEDPxE1?	MWi3NkBp	MYTEUXNQ	MXPJR\|UxRTFyIN88US=>	NF:4OYczOzh2NECzPC=>
T-84	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\INVAh\|ryP	MlrtO\|IhcA>?	MWrEUXNQ	NE\UUm9KSzVyPUGwJO69VQ>?	MXOyN\|g1PDB\|OB?=
NCI-H460	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6xNEDPxE1?	NVXDPXZwPzJiaB?=	MkPYSG1UVw>?	M3XmeWlEPTB;MUCg{txO	NEPOeWszOzh2NECzPC=>
Calu-6	M1exNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXzNVAh\|ryP	Mn;tO\|IhcA>?	MVfEUXNQ	MXXJR\|UxRTFyIN88US=>	NIHR[FYzOzh2NECzPC=>
HCC-2998	NXr4e41UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vGfVExKM7:TR?=	MUK3NkBp	NHXMfo1FVVOR	NGHQPYlKSzVyPUGwJO69VQ>?	MYWyN\|g1PDB\|OB?=
LS1034	NHvJPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDoUVYyOCEQvF2=	MoXBO\|IhcA>?	M3jUR2ROW09?	MkmxTWM2OD1zMDFOwG0>	MmDZNlM5PDRyM{i=
CHP-212	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNEDPxE1?	NUXTcGJJPzJiaB?=	NXr4Rm5JTE2VTx?=	Mn7mTWM2OD1zMDFOwG0>	MXWyN\|g1PDB\|OB?=
SK-N-AS	NEfyUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHWNVAh\|ryP	Mn3PO\|IhcA>?	MWTEUXNQ	NVvKUpA6UUN3ME2xNEDPxE1?	NX62cY1oOjN6NESwN\|g>
BFTC-905	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfCNVAh\|ryP	NIOxdnk4OiCq	MWrEUXNQ	NWP4[mZ2UUN3ME2xNEDPxE1?	Ml;iNlM5PDRyM{i=
HuT78	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLzNVAh\|ryP	M2[3b\|czKGh?	M4r5fGROW09?	Mn3YTWM2OD13MjDuUS=>	M4\aNFI{QDR2MEO4
RPMI-8226	NVq3[3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUOxNEDPxE1?	MnvpO\|IhcA>?	Mn\mSG1UVw>?	NXTuO2pbUUN3ME2yOlMhdk1?	NI\xWpYzOzh2NECzPC=>
BC-3	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\TNVAh\|ryP	MlzNO\|IhcA>?	NFG0W4ZFVVOR	M2DlXWlEPTB;Mke3JI5O	Mnf0NlM5PDRyM{i=
ACHN	NYLaVm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuy[YIyOCEQvF2=	NUPxc3J{PzJiaB?=	NVj1cGx{TE2VTx?=	MUfJR\|UxRTJ7NDDuUS=>	MoK3NlM5PDRyM{i=
JRT3-T35	M3;xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr3RXE3OTBizszN	NVm5TGhGPzJiaB?=	M4rMWWROW09?	NWnZWZZ[UUN3ME2yPVUhdk1?	NHHsXGQzOzh2NECzPC=>
SK-MES-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxNEDPxE1?	M{D6S\|czKGh?	MWDEUXNQ	MWXJR\|UxRTN{OTDuUS=>	NHXoOlQzOzh2NECzPC=>
CESS	M4nEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLmNVAh\|ryP	NWT5Uo9IPzJiaB?=	MVjEUXNQ	MULJR\|UxRTR7NzDuUS=>	MnfRNlM5PDRyM{i=
H4	M1v0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXWcIM1OTBizszN	NV\RfnJMPzJiaB?=	MknrSG1UVw>?	NGDU[pJKSzVyPU[xPUBvVQ>?	NVzQUohxOjN6NESwN\|g>
BC-1	NWHJcYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TufFExKM7:TR?=	MYC3NkBp	Mlf6SG1UVw>?	NWLBe5dSUUN3ME23NFQhdk1?	M4XtWlI{QDR2MEO4
DB	NGDiNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W3dVExKM7:TR?=	MWq3NkBp	NIfTfHZFVVOR	M4DOR2lEPTB;OEezJI5O	NFrOe3gzOzh2NECzPC=>
RPMI-6666	NUO1dHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjweWIyOCEQvF2=	M1mzUFczKGh?	NIPVU\|ZFVVOR	M{L2UmlEPTB;OUK4JI5O	NI\hRVAzOzh2NECzPC=>
MC/CAR	NUW1N2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TZblExKM7:TR?=	MWq3NkBp	MVzEUXNQ	MnTxTWM2OD1zLkCwNkDPxE1?	NWO5OWwyOjN6NESwN\|g>
SNU-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	NITzW5A4OiCq	NULpe2U2TE2VTx?=	MXLJR\|UxRTFwNUCxJO69VQ>?	MXeyN\|g1PDB\|OB?=
CEM/C1	M4TjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXiSJljOTBizszN	MYi3NkBp	NYO2eWFkTE2VTx?=	MXzJR\|UxRTFwN{ezJO69VQ>?	NInKVowzOzh2NECzPC=>
GDM-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XLWFExKM7:TR?=	M{m0eFczKGh?	M3\QUmROW09?	M3PQOGlEPTB;MT65PVch\|ryP	MnnrNlM5PDRyM{i=
HT-1080	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[xSmIyOCEQvF2=	Mk\CO\|IhcA>?	MWHEUXNQ	NULXemdHUUN3ME2yMlAxPCEQvF2=	Mnu5NlM5PDRyM{i=
HL-60	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[0O2MyOCEQvF2=	M4Xqb\|czKGh?	MWXEUXNQ	M1nKTGlEPTB;Mj6xO\|gh\|ryP	MlHMNlM5PDRyM{i=
C3A	NF;IWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVixNEDPxE1?	NYfaTFJHPzJiaB?=	Mk\xSG1UVw>?	MX\JR\|UxRTVwNEG0JO69VQ>?	NIrXS5EzOzh2NECzPC=>
MES-SA	M3vjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH2T\|IyOCEQvF2=	MVO3NkBp	MWLEUXNQ	MmHnTWM2OD14Lkm4PUDPxE1?	MmHVNlM5PDRyM{i=
22Rv1	NEXyWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4K2O\|ExKM7:TR?=	NFTzemY4OiCq	NIjDRo1FVVOR	NULEeXNvUUN3ME2xNEDPxE1?	M2DaZlI{QDR2MEO4
647-V	NFW1PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXpb3cyOCEQvF2=	MkXIO\|IhcA>?	NE\vWW1FVVOR	NX:zNHN3UUN3ME2xNEDPxE1?	M3jMVFI{QDR2MEO4
786-O	NX;lVnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXsNVAh\|ryP	Mnr3O\|IhcA>?	M4r5UWROW09?	MYXJR\|UxRTFyIN88US=>	MUmyN\|g1PDB\|OB?=
A172	NYf6U29lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T2SFExKM7:TR?=	NWLX[mxqPzJiaB?=	NFjXUmxFVVOR	MUTJR\|UxRTFyIN88US=>	NILy[oYzOzh2NECzPC=>
A204	M33nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKxNEDPxE1?	M2raOlczKGh?	M2mxVWROW09?	NYLKb3B7UUN3ME2xNEDPxE1?	NY[yTJZbOjN6NESwN\|g>
A427	M{DZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYqxNEDPxE1?	MYG3NkBp	NWXhSVBpTE2VTx?=	M4rCUmlEPTB;MUCg{txO	MXSyN\|g1PDB\|OB?=
A431	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUKxNEDPxE1?	NVLEVnR5PzJiaB?=	M4DvVWROW09?	MUfJR\|UxRTFyIN88US=>	MXqyN\|g1PDB\|OB?=
A2780	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPOOmNUOTBizszN	Ml[2O\|IhcA>?	M1fYRmROW09?	MnrDTWM2OD1zMDFOwG0>	NYrZRopjOjN6NESwN\|g>
ARH-77	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNEDPxE1?	NX73b3VGPzJiaB?=	NE[wcZpFVVOR	NVLpOVNbUUN3ME2xNEDPxE1?	MX[yN\|g1PDB\|OB?=
Be(2)C	NVnjS29ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TIdFExKM7:TR?=	MUe3NkBp	M3nHXmROW09?	M3PuXmlEPTB;MUCg{txO	MXqyN\|g1PDB\|OB?=
BT-20	NFvJb\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP4Wm4yOCEQvF2=	NXjsNIYzPzJiaB?=	NWXlb2VITE2VTx?=	MU\JR\|UxRTFyIN88US=>	NFvXcYYzOzh2NECzPC=>
BxPc3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGX0SZUyOCEQvF2=	NEPHVYc4OiCq	MVjEUXNQ	MWPJR\|UxRTFyIN88US=>	MVOyN\|g1PDB\|OB?=
C-4 I	NFuyfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXIWWFzOTBizszN	M1LiVFczKGh?	MXTEUXNQ	NXnrSXZ3UUN3ME2xNEDPxE1?	NEPn[nAzOzh2NECzPC=>
C33A	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVOyN2lxOTBizszN	NETwelg4OiCq	MXnEUXNQ	M1zLcWlEPTB;MUCg{txO	MofLNlM5PDRyM{i=
CAL-27	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;CV\|cyOCEQvF2=	MkfiO\|IhcA>?	NHzTTZFFVVOR	MV\JR\|UxRTFyIN88US=>	MonYNlM5PDRyM{i=
CAL-62	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixNEDPxE1?	NYKyOph6PzJiaB?=	NVL1[JpQTE2VTx?=	MlSzTWM2OD1zMDFOwG0>	MkLNNlM5PDRyM{i=
Calu-3	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rPXlExKM7:TR?=	M{DydlczKGh?	NELJXXZFVVOR	M1LZT2lEPTB;MUCg{txO	M1zR[\|I{QDR2MEO4
CaOV3	M{HPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjjbVEyOCEQvF2=	NFjWUFk4OiCq	NGfHcnRFVVOR	NV7aZ\|c1UUN3ME2xNEDPxE1?	MWmyN\|g1PDB\|OB?=
CGTHW1	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jDXlExKM7:TR?=	Mk\5O\|IhcA>?	NUfHcoFtTE2VTx?=	MnLZTWM2OD1zMDFOwG0>	MlfNNlM5PDRyM{i=
CHL-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PC[\|ExKM7:TR?=	MVK3NkBp	NF3M[IZFVVOR	MXzJR\|UxRTFyIN88US=>	M2jSe\|I{QDR2MEO4
Colo320DM	NYj3OWp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFyzVJYyOCEQvF2=	M4raPFczKGh?	NGLpcWFFVVOR	NH7CeVdKSzVyPUGwJO69VQ>?	NFzWdW8zOzh2NECzPC=>
Colo704	NGrNdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTTNVAh\|ryP	M{T0UlczKGh?	MXPEUXNQ	NGPLPWdKSzVyPUGwJO69VQ>?	M{OwTVI{QDR2MEO4
COR-L23	NFXXN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGxNEDPxE1?	NH\wPY84OiCq	MV;EUXNQ	NXfhUG8xUUN3ME2xNEDPxE1?	Mmi1NlM5PDRyM{i=
CRO-AP2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjPfVA1OTBizszN	M1O3fVczKGh?	NIDLNHJFVVOR	NGPJeJFKSzVyPUGwJO69VQ>?	NFnxN3kzOzh2NECzPC=>
Daudi	NEfRemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorENVAh\|ryP	NWDCeFA3PzJiaB?=	Mn;pSG1UVw>?	MmDnTWM2OD1zMDFOwG0>	NYPGTnh5OjN6NESwN\|g>
DOTC 24510	M4\N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGxNEDPxE1?	MlXKO\|IhcA>?	MlrnSG1UVw>?	Mne5TWM2OD1zMDFOwG0>	MofHNlM5PDRyM{i=
DU-145	NIe5[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVyxUHR[OTBizszN	NGSwepk4OiCq	MkGySG1UVw>?	M3HE[GlEPTB;MUCg{txO	M1rpb\|I{QDR2MEO4
EB-3	NYXqUVByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq5Uo5bOTBizszN	NULyZ4YyPzJiaB?=	MmjySG1UVw>?	NVfOW5hjUUN3ME2xNEDPxE1?	NEDkeXczOzh2NECzPC=>
EFM-19	NV\BNJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7rd2wyOCEQvF2=	MVO3NkBp	NI\PSINFVVOR	NI\rSnNKSzVyPUGwJO69VQ>?	M1HnWlI{QDR2MEO4
EKVX	NELte3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLtS4R{OTBizszN	NEfwOIw4OiCq	M2nhcWROW09?	NUL6WZJ7UUN3ME2xNEDPxE1?	Mk\XNlM5PDRyM{i=
FaDu	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\kNVAh\|ryP	MVS3NkBp	MlrXSG1UVw>?	NXXNfGtIUUN3ME2xNEDPxE1?	M4DNVFI{QDR2MEO4
G401	NHHtUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4foXVExKM7:TR?=	MoDrO\|IhcA>?	MXrEUXNQ	NHH1UFdKSzVyPUGwJO69VQ>?	NYDqelNVOjN6NESwN\|g>
HCC-70	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPofWgyOCEQvF2=	NGPOVmE4OiCq	NW\Pd4xSTE2VTx?=	M4XyNGlEPTB;MUCg{txO	MVyyN\|g1PDB\|OB?=
HCC-1954	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO2NVAh\|ryP	NWf5cWdQPzJiaB?=	NIXpS4VFVVOR	MUfJR\|UxRTFyIN88US=>	MXSyN\|g1PDB\|OB?=
Hela	NXvENWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jmXlExKM7:TR?=	MnjzO\|IhcA>?	MmTjSG1UVw>?	M{DZOWlEPTB;MUCg{txO	NWXLWnQ1OjN6NESwN\|g>
Hep3B	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNEDPxE1?	MoXDO\|IhcA>?	NHK1TlNFVVOR	Mk\pTWM2OD1zMDFOwG0>	NXjCd2RGOjN6NESwN\|g>
HMCB	NGDpUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	NFXHXHk4OiCq	MY\EUXNQ	NGjGcGJKSzVyPUGwJO69VQ>?	Mo\uNlM5PDRyM{i=
HN5	NHLVd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzaOFYyOCEQvF2=	Ml;hO\|IhcA>?	Ml7GSG1UVw>?	NX7CZ5JGUUN3ME2xNEDPxE1?	M{XadlI{QDR2MEO4
HOS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vL[lExKM7:TR?=	M{Dk[\|czKGh?	M13mdmROW09?	MkXETWM2OD1zMDFOwG0>	MkDjNlM5PDRyM{i=
HPAF-II	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfMNoFtOTBizszN	MVe3NkBp	MojpSG1UVw>?	M3Xke2lEPTB;MUCg{txO	MkDzNlM5PDRyM{i=
Hs746.T	NFLtPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnL4NVAh\|ryP	MV:3NkBp	MnTySG1UVw>?	M17pcWlEPTB;MUCg{txO	MUGyN\|g1PDB\|OB?=
HT	M{H0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGxNEDPxE1?	NIrme4g4OiCq	MkTaSG1UVw>?	NXXoSo5TUUN3ME2xNEDPxE1?	MXSyN\|g1PDB\|OB?=
HT-3	NUDSS25yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXoNVAh\|ryP	MWO3NkBp	M4rkeGROW09?	M4X5UWlEPTB;MUCg{txO	MmGwNlM5PDRyM{i=
HuNS-1	NWfIdXJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSxNEDPxE1?	NIfuWXE4OiCq	NVXadlZITE2VTx?=	NH;NcZlKSzVyPUGwJO69VQ>?	NHnSOoYzOzh2NECzPC=>
IGROV1	NEfITJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPMNVAh\|ryP	NFvXW3E4OiCq	NHXHV3FFVVOR	NETYfJlKSzVyPUGwJO69VQ>?	NVzONlFGOjN6NESwN\|g>
J82	NGfrb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv0NVAh\|ryP	NHfKXI04OiCq	NHHBPJRFVVOR	NFHQSHBKSzVyPUGwJO69VQ>?	MXOyN\|g1PDB\|OB?=
JM1	NHjVRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzSR4pnOTBizszN	M{HMclczKGh?	NWrGXWw{TE2VTx?=	M1\PNGlEPTB;MUCg{txO	NULP[YUyOjN6NESwN\|g>
Kato III	NF3GdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOxNEDPxE1?	NGW4R5A4OiCq	Mly1SG1UVw>?	NHvVV45KSzVyPUGwJO69VQ>?	NX\zTVIxOjN6NESwN\|g>
KHOS-240S	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjtNVAh\|ryP	NETNOoo4OiCq	NY\NVmZFTE2VTx?=	NUG0VYtyUUN3ME2xNEDPxE1?	MUSyN\|g1PDB\|OB?=
KM-12	NVribnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfKPZB{OTBizszN	NWTsXG1EPzJiaB?=	NFjMeIdFVVOR	MYLJR\|UxRTFyIN88US=>	NFnocoUzOzh2NECzPC=>
KPL-1	M1TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2xNEDPxE1?	MV[3NkBp	M3HtW2ROW09?	M{XyOGlEPTB;MUCg{txO	Mn3ENlM5PDRyM{i=
KYSE-30	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXuxNEDPxE1?	MnnVO\|IhcA>?	MmXaSG1UVw>?	MWTJR\|UxRTFyIN88US=>	NIP0SoQzOzh2NECzPC=>
LNCaP	MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XJXlExKM7:TR?=	M2fWPVczKGh?	NHrhN5JFVVOR	MkfrTWM2OD1zMDFOwG0>	Mn\0NlM5PDRyM{i=
MCF-7	NXWxPZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;WNVAh\|ryP	NF:xZ4w4OiCq	MVHEUXNQ	MnyzTWM2OD1zMDFOwG0>	MonnNlM5PDRyM{i=
MC-IXC	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4T5TFExKM7:TR?=	M2O5PFczKGh?	NGexOlhFVVOR	NHW4cXZKSzVyPUGwJO69VQ>?	MkGyNlM5PDRyM{i=
MDA-MB-175 VII	NXi0NnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mln1NVAh\|ryP	NITaVIw4OiCq	Mo\zSG1UVw>?	MYXJR\|UxRTFyIN88US=>	NYPS[G5nOjN6NESwN\|g>
MDA-MB-468	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPpNJAyOCEQvF2=	M2ewcFczKGh?	NH6yZ2pFVVOR	MWjJR\|UxRTFyIN88US=>	M3;vRlI{QDR2MEO4
MiaPaCa	M4HxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnLZZBuOTBizszN	MX63NkBp	MkTSSG1UVw>?	NWPvcYJoUUN3ME2xNEDPxE1?	Mlu1NlM5PDRyM{i=
Molt-4	NUjwPYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoKyNVAh\|ryP	MmnBO\|IhcA>?	NFvVdW1FVVOR	M3Hr[2lEPTB;MUCg{txO	M3nvXVI{QDR2MEO4
NCI-ADR/RES	NVrQNlRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmryNVAh\|ryP	MorQO\|IhcA>?	MmTvSG1UVw>?	M1LRNWlEPTB;MUCg{txO	NUHuSFNQOjN6NESwN\|g>
NCI-H69	M2\BWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLkVoUyOCEQvF2=	NYDFO3NXPzJiaB?=	M1riV2ROW09?	Ml3zTWM2OD1zMDFOwG0>	M33pUFI{QDR2MEO4
NCI-H82	NWHNeVcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\pOpV4OTBizszN	MXK3NkBp	MXjEUXNQ	MVvJR\|UxRTFyIN88US=>	M{\ucFI{QDR2MEO4
NCI-N87	M{THcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W3eFExKM7:TR?=	NWTRe4loPzJiaB?=	NV;5TYEyTE2VTx?=	MXfJR\|UxRTFyIN88US=>	NYOwfZl1OjN6NESwN\|g>
NCI-H146	NV;NSW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYOxNEDPxE1?	M3Hv[VczKGh?	M4j6W2ROW09?	MmXQTWM2OD1zMDFOwG0>	NXz4UpV4OjN6NESwN\|g>
NCI-H157	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixNEDPxE1?	MkHPO\|IhcA>?	NXG1NFBSTE2VTx?=	NYrlSmFxUUN3ME2xNEDPxE1?	NYr0UHdKOjN6NESwN\|g>
NCI-H187	NWfBWHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;I[\|ExKM7:TR?=	NGnjUXY4OiCq	MXrEUXNQ	M4O1dGlEPTB;MUCg{txO	M1z1fVI{QDR2MEO4
NCI-H209	M1;LS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVuxNEDPxE1?	NVvte5BqPzJiaB?=	M4jRN2ROW09?	MWXJR\|UxRTFyIN88US=>	MVSyN\|g1PDB\|OB?=
NCI-H226	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml36NVAh\|ryP	Mn3SO\|IhcA>?	MXTEUXNQ	MWXJR\|UxRTFyIN88US=>	M17VNFI{QDR2MEO4
NCI-H292	NXW4UoRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7vNVAh\|ryP	M33zO\|czKGh?	NIjPfGNFVVOR	MoLHTWM2OD1zMDFOwG0>	NEiwXW4zOzh2NECzPC=>
NCI-H322	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSxNEDPxE1?	NVHsPHhSPzJiaB?=	NFL2bIZFVVOR	M{i4UGlEPTB;MUCg{txO	NVi4T2J3OjN6NESwN\|g>
NCI-H358	NGHHPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnIV3c2OTBizszN	Mkf6O\|IhcA>?	M{nhTGROW09?	NVrje2VqUUN3ME2xNEDPxE1?	MVeyN\|g1PDB\|OB?=
NCI-H520	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[2OlExKM7:TR?=	MYW3NkBp	MoTBSG1UVw>?	MmOzTWM2OD1zMDFOwG0>	MUeyN\|g1PDB\|OB?=
NCI-H526	M4nLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfqd\|MyOCEQvF2=	MXK3NkBp	Ml:zSG1UVw>?	NUTiToZIUUN3ME2xNEDPxE1?	NInYbFgzOzh2NECzPC=>
NCI-H630	M{DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPQeItQOTBizszN	Mnq4O\|IhcA>?	MVjEUXNQ	Ml\aTWM2OD1zMDFOwG0>	MkDQNlM5PDRyM{i=
NCI-H661	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[xNEDPxE1?	MWG3NkBp	MUTEUXNQ	M2PzbGlEPTB;MUCg{txO	M{Xhb\|I{QDR2MEO4
NCI-H716	NGTld2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7UNVAh\|ryP	MmeyO\|IhcA>?	MoDCSG1UVw>?	NUP3elIzUUN3ME2xNEDPxE1?	NWDOS5k2OjN6NESwN\|g>
NCI-H1563	NX:yV\|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn63NVAh\|ryP	NYnzVXNkPzJiaB?=	NES3U5NFVVOR	NVvHTYczUUN3ME2xNEDPxE1?	Ml;ENlM5PDRyM{i=
NCI-H1792	NXzCS\|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	MVm3NkBp	MV;EUXNQ	NHThW4lKSzVyPUGwJO69VQ>?	NH;ORWEzOzh2NECzPC=>
NCI-H2030	NXjrdYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LNeFExKM7:TR?=	M3zHPVczKGh?	M1;PW2ROW09?	MX;JR\|UxRTFyIN88US=>	M32wRVI{QDR2MEO4
NCI-H2052	NInETFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorjNVAh\|ryP	M{THOVczKGh?	MYjEUXNQ	NULzdItGUUN3ME2xNEDPxE1?	M2\mc\|I{QDR2MEO4
NCI-H2122	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfoRnBkOTBizszN	MoLTO\|IhcA>?	MmLUSG1UVw>?	NE[0bVFKSzVyPUGwJO69VQ>?	NXn2W2hJOjN6NESwN\|g>
NCI-H2228	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXSNVAh\|ryP	NF3HUIM4OiCq	MYjEUXNQ	NXzaVpoxUUN3ME2xNEDPxE1?	NWLZ[XRrOjN6NESwN\|g>
OE-19	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHf2V\|UyOCEQvF2=	M4L2ZlczKGh?	NXrEWIVnTE2VTx?=	NWTJ[VMxUUN3ME2xNEDPxE1?	NV;F[mZQOjN6NESwN\|g>
OE-21	M1fFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf5VHUyOCEQvF2=	NWH3Z5dvPzJiaB?=	M1HnNWROW09?	MljETWM2OD1zMDFOwG0>	M{LXWFI{QDR2MEO4
OE-33	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7sS3lNOTBizszN	NX;Re\|ZlPzJiaB?=	Mo\wSG1UVw>?	NUHSSHZtUUN3ME2xNEDPxE1?	NUfIWHh[OjN6NESwN\|g>
OVCAR-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLxd3cyOTBizszN	MlzsO\|IhcA>?	NIWwfVBFVVOR	NVrDPXl3UUN3ME2xNEDPxE1?	MkX2NlM5PDRyM{i=
OVCAR-4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\TdZh{OTBizszN	NIXyeIk4OiCq	NH;n[GRFVVOR	NX\2W3p6UUN3ME2xNEDPxE1?	MUeyN\|g1PDB\|OB?=
OVCAR-5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSzNVAh\|ryP	NYmzfId5PzJiaB?=	Mmm0SG1UVw>?	Ml7mTWM2OD1zMDFOwG0>	NFHuOIgzOzh2NECzPC=>
P3HR-1	NUH4TYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFP4ZYEyOCEQvF2=	Mn71O\|IhcA>?	NEHkTG1FVVOR	NXrMRlJrUUN3ME2xNEDPxE1?	NXS0cGtjOjN6NESwN\|g>
PC-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnpNVAh\|ryP	NF7JTGQ4OiCq	MX\EUXNQ	MnG1TWM2OD1zMDFOwG0>	NFq1fFEzOzh2NECzPC=>
Raji	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ixU\|ExKM7:TR?=	NUL1R5o4PzJiaB?=	MYDEUXNQ	M4S0WGlEPTB;MUCg{txO	MkOxNlM5PDRyM{i=
RD	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTJVYVzOTBizszN	NYfZdINMPzJiaB?=	MUnEUXNQ	MWjJR\|UxRTFyIN88US=>	MnjJNlM5PDRyM{i=
RD-ES	NF75UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK0[YQyOCEQvF2=	NXX1OVE1PzJiaB?=	NE\jOJRFVVOR	MluwTWM2OD1zMDFOwG0>	MkG3NlM5PDRyM{i=
RL	NX[0fohsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfzWpBLOTBizszN	M13Xd\|czKGh?	NXTyb5R[TE2VTx?=	M2j4bWlEPTB;MUCg{txO	MkX0NlM5PDRyM{i=
SaOS2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnSNVAh\|ryP	NV\MWXF[PzJiaB?=	M1m1[GROW09?	NXO1cVhGUUN3ME2xNEDPxE1?	Ml3nNlM5PDRyM{i=
SCC-9	Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1exR\|ExKM7:TR?=	MnPxO\|IhcA>?	M3W5b2ROW09?	M4PhTGlEPTB;MUCg{txO	MUWyN\|g1PDB\|OB?=
SCC-12	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DCW\|ExKM7:TR?=	MYm3NkBp	NEHpUndFVVOR	NWXkSVJ1UUN3ME2xNEDPxE1?	MoTkNlM5PDRyM{i=
SCC-13	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixNEDPxE1?	NE\xOGk4OiCq	M{nnSGROW09?	NYi0WGtsUUN3ME2xNEDPxE1?	MmfFNlM5PDRyM{i=
SCC-15	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrRNYVUOTBizszN	MVi3NkBp	M4Lxd2ROW09?	M2rxcGlEPTB;MUCg{txO	MVKyN\|g1PDB\|OB?=
SCC-25	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILsN2MyOCEQvF2=	MmizO\|IhcA>?	MV\EUXNQ	NX\iPWNYUUN3ME2xNEDPxE1?	NV3iRnREOjN6NESwN\|g>
SCLC-3	NUDMdmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnkNVAh\|ryP	MmPBO\|IhcA>?	NETJUlZFVVOR	M2XpbmlEPTB;MUCg{txO	NGi1OZUzOzh2NECzPC=>
SF-268	NV;YboJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD3NVAh\|ryP	M4nKeFczKGh?	Mkj1SG1UVw>?	MXfJR\|UxRTFyIN88US=>	NEjM[HYzOzh2NECzPC=>
SF-295	NHHTZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPaOnkyOCEQvF2=	MYe3NkBp	NXvrVIhCTE2VTx?=	MYrJR\|UxRTFyIN88US=>	NWXFZ\|lnOjN6NESwN\|g>
SJRH30	NW\jfWZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Wy[VExKM7:TR?=	MkHFO\|IhcA>?	M{OzXWROW09?	NUPCNox3UUN3ME2xNEDPxE1?	NEGzT4UzOzh2NECzPC=>
SK-BR-3	NWnySGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3WeJZ7OTBizszN	MmLRO\|IhcA>?	NGrQNVVFVVOR	MWPJR\|UxRTFyIN88US=>	Ml;qNlM5PDRyM{i=
SK-LMS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvxUlAyOCEQvF2=	MoHEO\|IhcA>?	MYHEUXNQ	MU\JR\|UxRTFyIN88US=>	MViyN\|g1PDB\|OB?=
SK-N-DZ	NEXOWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLJNVAh\|ryP	MVm3NkBp	NHexRXFFVVOR	MUPJR\|UxRTFyIN88US=>	NYfIUY1XOjN6NESwN\|g>
SK-N-F1	NWHRPGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzSc\|cyOTBizszN	MYi3NkBp	MlfaSG1UVw>?	MkXkTWM2OD1zMDFOwG0>	NVzBbmJvOjN6NESwN\|g>
SKOV-3	NX\4UYo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjUNVAh\|ryP	NYDBclRTPzJiaB?=	Mly5SG1UVw>?	MVnJR\|UxRTFyIN88US=>	MkjlNlM5PDRyM{i=
SK-UT-1	NIW2V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGxNEDPxE1?	NV\3RZBrPzJiaB?=	M2T2XWROW09?	NEfSPVNKSzVyPUGwJO69VQ>?	NFHkUG4zOzh2NECzPC=>
SN12C	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVyxNEDPxE1?	M{W0V\|czKGh?	NIn0cpZFVVOR	MljwTWM2OD1zMDFOwG0>	MUCyN\|g1PDB\|OB?=
SNB-19	M17KRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\UblIyOCEQvF2=	NED4NlE4OiCq	MV7EUXNQ	MmnBTWM2OD1zMDFOwG0>	MUmyN\|g1PDB\|OB?=
SNU-5	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e3OVExKM7:TR?=	NX7QUlFyPzJiaB?=	MVrEUXNQ	M3fSWmlEPTB;MUCg{txO	M{\ZeVI{QDR2MEO4
SNU-16	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17OdVExKM7:TR?=	NHS2epA4OiCq	M3zLdmROW09?	M{LjSWlEPTB;MUCg{txO	M3XZWFI{QDR2MEO4
SNU-398	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixNEDPxE1?	NWrLVmtHPzJiaB?=	NYLrZYFCTE2VTx?=	MVnJR\|UxRTFyIN88US=>	M4LtZ\|I{QDR2MEO4
SNU-449	NYXYe245T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL6WnBQOTBizszN	NFviO3I4OiCq	MmfRSG1UVw>?	NH7XN2hKSzVyPUGwJO69VQ>?	NUKzcWhiOjN6NESwN\|g>
SR	M1PBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfOZlN4OTBizszN	M1S3WlczKGh?	NGOwOZZFVVOR	NWHRTXRiUUN3ME2xNEDPxE1?	MXWyN\|g1PDB\|OB?=
ST486	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzxTm9YOTBizszN	MUS3NkBp	NGLJdVVFVVOR	NVzpNnV2UUN3ME2xNEDPxE1?	MkXVNlM5PDRyM{i=
SW579	M3XseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFi4SIQyOCEQvF2=	MoHzO\|IhcA>?	NIDhTFZFVVOR	M{LzNGlEPTB;MUCg{txO	MnPBNlM5PDRyM{i=
SW684	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlSwNVAh\|ryP	MVS3NkBp	MmHaSG1UVw>?	M1rTb2lEPTB;MUCg{txO	NHXRdXAzOzh2NECzPC=>
SW-780	M{TzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEK3U5UyOCEQvF2=	MVm3NkBp	MnPmSG1UVw>?	NEG0V4NKSzVyPUGwJO69VQ>?	MYKyN\|g1PDB\|OB?=
SW900	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HNNFExKM7:TR?=	MYK3NkBp	MlTISG1UVw>?	M{jDN2lEPTB;MUCg{txO	MXSyN\|g1PDB\|OB?=
SW1088	NXHkO2VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfhNVAh\|ryP	MoK2O\|IhcA>?	Mn22SG1UVw>?	NVnCVZNiUUN3ME2xNEDPxE1?	NYHtZZk1OjN6NESwN\|g>
SW1463	NH7FRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuxNEDPxE1?	M3nZUlczKGh?	MXrEUXNQ	NVXhUmJGUUN3ME2xNEDPxE1?	NGLsWXYzOzh2NECzPC=>
SW1990	MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfZ[lJvOTBizszN	MXq3NkBp	NFX3T4JFVVOR	MnrITWM2OD1zMDFOwG0>	NUnubpdCOjN6NESwN\|g>
T47D	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknENVAh\|ryP	NWjxfIVUPzJiaB?=	M1rPdGROW09?	NWO0RYpFUUN3ME2xNEDPxE1?	NIPrXlMzOzh2NECzPC=>
TE381.T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\McJoyOCEQvF2=	MmfGO\|IhcA>?	NEPFR2VFVVOR	NV\wOpQ4UUN3ME2xNEDPxE1?	NYjCbFUzOjN6NESwN\|g>
TK-10	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XK[lExKM7:TR?=	M4rrcFczKGh?	MV\EUXNQ	MU\JR\|UxRTFyIN88US=>	M2DsVlI{QDR2MEO4
U2OS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\YdVExKM7:TR?=	NXL0WHQyPzJiaB?=	NX7kdGZ{TE2VTx?=	MXzJR\|UxRTFyIN88US=>	NY[1VWVwOjN6NESwN\|g>
U251	M3TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[xNEDPxE1?	M{nFd\|czKGh?	NETBO3JFVVOR	NVPEV\|NtUUN3ME2xNEDPxE1?	NEXLclkzOzh2NECzPC=>
UACC-812	NHrM[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zFVVExKM7:TR?=	MY[3NkBp	NILabpRFVVOR	MXTJR\|UxRTFyIN88US=>	NXTJWI0zOjN6NESwN\|g>
YAPC	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[5RlExKM7:TR?=	NXfRb4tYPzJiaB?=	NVPHW2tqTE2VTx?=	M4HC[GlEPTB;MUCg{txO	MnzYNlM5PDRyM{i=
ZR-75-1	NY\lNIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW4VGpIOTBizszN	MYW3NkBp	M4q3PGROW09?	NV\ueXM3UUN3ME2xNEDPxE1?	MlzRNlM5PDRyM{i=
A375	M3TwbWZ2dmO2aX;uJIF{e2G7	NV\mPY5sOS5{IN88US=>	NHzmO3Q1KGh?	MlXTSG1UVw>?	NIDvUohKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?=	MoDCNlI{QDl2N{G=
YUSIT1	M320T2Z2dmO2aX;uJIF{e2G7			NHrsOmFFVVOR	MXTy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0>	MmDNNlI{QDl2N{G=
MeWo	M{C4PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MXLEUXNQ	M{HBbmlEPTBiPTC5PFchdk1?	NYLwXIs{OjZyMUi1NlQ>
WiDr	M3zaVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWrEUXNQ	NFXGbFFKSzVyIE2gO\|Yhdk1?	NGexNo4zPjBzOEWyOC=>
Colo-205	M{nVbmZ2dmO2aX;uJIF{e2G7	NWK0cIl[OSEQvF2=	NWjweJlvPCCm	NUXFZnp3TE2VTx?=	MX;JcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU>	NHLDTYwzPTN6MUG1Ni=>
RBW-1	NECwd4hHfW6ldHnvckBie3OjeR?=	MYCxJO69VQ>?		MYjEUXNQ	NY\1Wnh3Vm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w	MX2yOFg5PTZ7MB?=
RBO-1	MV\GeY5kfGmxbjDhd5NigQ>?	M2fGPVEh\|ryP		M2DxemROW09?	Ml:zTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MV6yOFg5PTZ7MB?=
RBO-2	NHPtZXRHfW6ldHnvckBie3OjeR?=	Moi0NUDPxE1?		MV\EUXNQ	MVvJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MWCyOFg5PTZ7MB?=
RBOW	NIrR[JpHfW6ldHnvckBie3OjeR?=	M2jWO\|Eh\|ryP		NIC2eZBFVVOR	Mm\yTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NGnpcIUzPDh6NU[5NC=>
M257	NUPudnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HPNVExOCCwTR?=	MXS3NkBp		NFm0[4JFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	M2XON\|I{OzF5NES2
LCP	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkP4NVAxKG6P	NEPYOno4OiCq		MXPJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u	NFXvSJYzOzNzN{S0Oi=>
WM266	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\LfW0yODBibl2=	MXm3NkBp		Ml;4TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKFePMk[2JINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEHEJI12fGGwdHH0bY9v	NYfYS4w{OjN\|MUe0OFY>
M257	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\VNVAxKG6P	NITxbmc4OiCq		NEnSRVVFd2W\|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NYTae3RROjN\|MUe0OFY>
LCP	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHeyRVMyODBibl2=	M4\LPFczKGh?		MoLZTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MYiyN\|MyPzR2Nh?=
WM266	NXHmPXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUKxNFAhdk1?	M3PLWFczKGh?		MlrZTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w	NWP2RpBHOjN\|MUe0OFY>

... Click to View More Cell Line Experimental Data

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03794297	Not yet recruiting	BRAF NP_004324.2:p.V600X\|Erdheim-Chester Disease	National Cancer Institute (NCI)	January 12 2020	Phase 2
NCT03794297	Not yet recruiting	BRAF NP_004324.2:p.V600X\|Erdheim-Chester Disease	National Cancer Institute (NCI)	January 12 2020	Phase 2
NCT03784014	Not yet recruiting	Soft Tissue Sarcoma	Institut National de la Santé Et de la Recherche Médicale France\|Commissariat A L''energie Atomique\|Institut Bergonié\|Plateforme labellisée Inca – Institut Bergonié Bordeaux\|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris\|CIC-EC 1401/EUCLID	March 2019	Phase 3
NCT03784014	Not yet recruiting	Soft Tissue Sarcoma	Institut National de la Santé Et de la Recherche Médicale France\|Commissariat A L''energie Atomique\|Institut Bergonié\|Plateforme labellisée Inca – Institut Bergonié Bordeaux\|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris\|CIC-EC 1401/EUCLID	March 2019	Phase 3
NCT03272464	Recruiting	Melanoma	Massachusetts General Hospital\|Incyte Corporation	November 30 2018	Phase 1
NCT03272464	Recruiting	Melanoma	Massachusetts General Hospital\|Incyte Corporation	November 30 2018	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products3

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523, VRT752271) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 21 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 21 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)